The Table below was published in e-book
International Pulmonologist’s Consensus On Covid-19 2nd ed 2020
on April 22nd 2020 (ed. Tinku Joseph).
Summary of currently available drugs which can be potentially used for treatment of COVID-19
Disclaimer: The options listed below are not licensed for the treatment of COVID-19
|Agent||Classification||Mechanism of action||Dosage||Side effects|
|Hydroxychloroquine||Off label use||Hampers low pH dependent steps of viral replication||400 mg BID x 2 doses, then 200 mg BID for 5days||QT prolongation|
|Oseltamivir||No trials on COVID-19||Neuraminidase enzyme inhibitor in influenza||75mg BID for 5 days||GI intolerance Headache Insomnia|
|Remdesivir||Investigational (can be used only on compassionate basis)||RNA dependent RNA polymerase inhibitor||200 mg IV loading dose, then 100mgIV daily, up to 10 days||GI intolerance Hepatotoxicity|
|Off label use||3CLpro (viral protease) inhibitor||400/100 mg BID for up to 10 days||QT prolongation Hepatotoxicity|
|Interferon Beta B1||Off label use||Immunomodulatory; enhancement of innate and adaptive viral immunity||Flu like syndrome depression|
|Tocilizumab||Off label use||Monoclonal antibody to IL6 receptor / treats cytokine release syndrome||4-8 mg/kg (max 400mg) IV and can be repeated up to three times 8 hours apart||Elevation of liver enzymes Increased risk of re-activation of other respiratory infections|
|Initiate as per institution based||Secondary bacterial infection (CAP)/VAP|
|Corticosteroids||Not indicated in treating SARS CoV2 as per available evidence. Might prolong viral shedding.
Use as per indicated in refractory shock/macrophage activation syndrome/if patient has other indications for steroid use
|Convalescent Plasma with neutralizing antibody||Off label use||Antibodies from convalescent plasma might suppress viraemia. Theoretically: Better to start at early stage of disease||Consider IVIG at standard dose of 1 gm/kg daily x 2 doses||Might interact with antivirals|